British American Tobacco earnings date
British American Tobacco (BMTA) Q2 2026 Earnings Report
DE:BMTA Q2 2026 EPS Results
- Actual EPS
- EUR 2.04
- Consensus EPS
- EUR 1.94
- Beat/Miss
- Beat by +EUR 0.10
- One Year Ago EPS
- EUR 1.95
DE:BMTA Q2 2026 Revenue Results
- Actual Revenue
- EUR 14.93B
- Expected Revenue
- EUR 14.90B
- Beat/Miss
- Beat by +EUR 32.22M
- YoY Revenue Growth
- +5.16%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 07/30/2026
- Time
- Before Open
- Conference Call
- Thursday, July 30, 2026
British American Tobacco's next earnings date is estimated for February 11, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call presented multiple clear progress points: strong New Category growth (notably Modern Oral), solid US multi-category performance, margin expansion, improved cash generation, and a defined Fit2Win savings trajectory. These positives are balanced by material near-term challenges: declines in Heated Products and Vapour revenues in some regions, APMEA profit pressure, combustible volume declines and market-specific shocks (e.g., Brazil excise), ongoing regulatory and illicit market issues, and sizable one-off/non-cash charges. Management reiterated confidence in recovery and a pathway to return to the midterm algorithm while emphasizing targeted investments for sustainable growth.
Guidance: management expects a H2‑weighted recovery with adjusted profit from operations accelerating in H2 and full‑year adjusted EPS now expected toward the middle of the 5–8% range, while revenue and operating profit are expected at the lower end of the algorithm after absorbing c.1% transactional FX headwind; key H2 drivers are mid‑teens New Category revenue growth (after H1 New Categories +18% and Modern Oral +66%), an AME acceleration and APMEA sequential recovery, plus positive phasing of Fit2Win benefits. Financial targets include net finance cost of c.£1.65bn, an underlying tax rate of 24–25%, reaching target leverage of 2.0–2.5x by year‑end, a £1.3bn 2026 share buyback alongside the progressive dividend, and a commitment to deliver >£50bn free cash flow by 2030; Fit2Win is now expected to deliver £700m annualized savings by 2028 (£500m by 2027) with total one‑off costs ~£950m (£840m adjusting).
- Smokeless Revenue Progress and Consumer AddsSmokeless now represents 19.8% of group revenue (up 160 basis points year-on-year). The business added 4.1 million smokeless consumers over the last 12 months, taking the total to 35 million, driven mainly by Modern Oral and the Velo brand.
- New Categories: Strong Growth and ProfitabilityNew categories revenue accelerated to +18% (Modern Oral +66%; Vapour +5.3%). New category contribution increased 55% to GBP 269 million and gross profit in the category rose by over GBP 120 million, reflecting improved scale and targeted investment.
- Solid Group Financial Performance (Adjusted)Group constant-currency results: revenue +2.9%, adjusted gross profit +3.8%, adjusted profit from operations +3.5%, and adjusted diluted EPS +7.9%. Full-year EPS guidance upgraded to the middle of the 5%–8% range.
- US Multi-Category StrengthUS total revenue +8.5% and adjusted operating profit +10.1%. US New Category revenue nearly +60% (Velo Plus +200%; Vuse returned to double-digit volume and revenue growth). Vuse extended Vapour value share to a record 55.9%.
- Combustibles Price/Mix and Revenue ResilienceCombustible revenue grew 2.1% despite combustibles volume decline of 4.7%; price/mix contributed +6.8%. Strong price/mix and cost optimization supported adjusted gross profit growth ahead of revenue.
- Margin Progress and Fit2Win TransformationGroup operating margin expanded 30 basis points to 43.7% (10 bps expansion at current rates). Fit2Win savings now expected GBP 700 million annualized by 2028 (GBP 500 million by 2027); identified a further GBP 100 million of optimization savings.
- Cash Generation, Leverage and Shareholder ReturnsStrong cash conversion (>95% target), on track to be within 2.0–2.5x leverage corridor by year-end. Committed GBP 1.3 billion share buyback in 2026, progressive dividend maintained, and ambition to deliver >GBP 50 billion free cash flow by 2030.
- Modern Oral Global Leadership and ScaleBAT shipped 7.9 billion Modern Oral pouches in H1. Modern Oral top-market volume share increased by over 8 percentage points to 39%; in AME BAT holds 62% volume share across top markets and 68.5% value share. Velo captures ~90% of Modern Oral value growth in the US.
DE:BMTA Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 11, 2027 | 2026 (Q4) | 2.35- | 2.31 | ― | ― |
| Jul 30, 2026 | 2026 (Q2) | 1.942.04 | 1.95 | 4.60% (+0.09) | |
| Feb 12, 2026 | 2025 (Q4) | 2.282.31 | -0.77 | 401.18% (+3.08) | |
| Jul 31, 2025 | 2025 (Q2) | 2.011.95 | 1.98 | -1.24% (-0.02) | |
| Feb 13, 2025 | 2024 (Q4) | 2.21-0.77 | -9.35 | 91.78% (+8.58) | |
| Jul 25, 2024 | 2024 (Q2) | 1.981.98 | 2.13 | -7.12% (-0.15) | |
| Feb 08, 2024 | 2023 (Q4) | 2.26-9.35 | 1.16 | -905.47% (-10.51) | |
| Jul 26, 2023 | 2023 (Q2) | 2.032.13 | 1.83 | 16.53% (+0.30) | |
| Feb 09, 2023 | 2022 (Q4) | 2.231.16 | 2.15 | -45.99% (-0.99) | |
| Jul 27, 2022 | 2022 (Q2) | 1.851.83 | 1.94 | -5.84% (-0.11) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


